1 study found for:    Crenolanib AND GIST | Open Studies
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene
Condition: D842-related Mutant GIST
Intervention: Drug: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID

Indicates status has not been verified in more than two years